Ajanta Pharma Limited (NSE:AJANTPHARM)

India flag India · Delayed Price · Currency is INR
2,756.30
-50.90 (-1.81%)
Apr 28, 2026, 3:29 PM IST
3.00%
Market Cap 344.19B
Revenue (ttm) 52.02B
Net Income (ttm) 10.15B
Shares Out 124.89M
EPS (ttm) 81.21
PE Ratio 33.94
Forward PE 29.03
Dividend 28.00 (1.00%)
Ex-Dividend Date Nov 10, 2025
Volume 45,412
Average Volume 85,057
Open 2,822.00
Previous Close 2,807.20
Day's Range 2,740.80 - 2,825.00
52-Week Range 2,329.90 - 3,228.00
Beta 0.24
RSI 47.73
Earnings Date May 5, 2026

About Ajanta Pharma

Ajanta Pharma Limited, together with its subsidiaries, a pharmaceutical formulation company that develops, manufactures, and markets specialty pharmaceutical finished dosages. The company offers chronic and acute therapies; branded generic products; and a range of dosage forms, including tablets, capsules, injectables, inhalers, ointments, creams, and liquids. It also serves various therapeutic areas comprising cardiology, dermatology, ophthalmology, and pain management. The company operates in India, Africa, Asia, the United States, and intern... [Read more]

Sector Healthcare
Founded 1973
Employees 9,628
Stock Exchange National Stock Exchange of India
Ticker Symbol AJANTPHARM
Full Company Profile

Financial Performance

In fiscal year 2025, Ajanta Pharma's revenue was 46.48 billion, an increase of 10.44% compared to the previous year's 42.09 billion. Earnings were 9.20 billion, an increase of 12.77%.

Financial Statements

News

Ajanta Pharma receives five observations from US FDA after facility inspection

Ajanta Pharma has announced that the US Food and Drug Administration (FDA) concluded an inspection at its manufacturing facility in Paithan, Maharashtra. The inspection, which took place from 13th Apr...

6 days ago - Business Upturn

Pharma sector stocks today, April 21: Wockhardt surge 2.08%, Natco Pharma down 1.86%, Ajanta Pharma up 1.10%

The Indian pharma sector opened on a mixed note on April 21, 2026 (as of 9:43 AM). The S&P BSE Healthcare Index stood at 43,475.50, up 0.23%, while the NIFTY…

7 days ago - Business Upturn

Pharma sector stocks today, April 16: Ajanta Pharma down 1.53%, Glenmark Pharma falls 1.23%, Lupin drops 1.08%

The S&P BSE Healthcare index is marginally in the red at -0.10% in early trade, while broader markets (Sensex +0.52%, Nifty 50 +0.39%) are positive. Most losses in the pharma…

12 days ago - Business Upturn

Pharma sector stocks fall today, April 13: Biocon falls 2.35%, Cipla down 1.66%, Ajanta Pharma gains 0.77%

Pharmaceutical sector stocks traded mostly lower in early trade on Monday, April 13, 2026, with most counters under pressure. The S&P BSE Healthcare Index declined 0.88% to 42,246.47, while the…

15 days ago - Business Upturn

Pharma sector stocks today, March 23: Alembic Pharma down 2.24%, Ajanta Pharma falls 1.85%, Glenmark Pharma falls 1.98%

The pharmaceutical sector in India experienced a downturn on March 23, 2026, as reflected in early morning trading data from BSE and NSE around 9:29-9:30 AM IST. Most listed pharma…

5 weeks ago - Business Upturn

Pharma sector stocks today, March 17: Emcure Pharma surge 2.42%, Ajanta Pharma up 2.14%, Strides Pharma down 2.22%

The Indian pharmaceutical sector showed mixed performance on March 17, 2026, during early trading hours. The data reflects prices as of approximately 9:34 AM IST, with the S&P BSE HEALTHCARE…

6 weeks ago - Business Upturn

Pharma sector stocks today, March 13: Laurus Labs down 2.56%, Ajanta Pharma falls 1.88%, Granules India drops 2.14%

The Indian pharmaceutical sector showed a downward trend in early trading on March 13, 2026, aligning with broader market weakness. The S&P BSE Healthcare Index stood at 43,441.0, down 0.6%…

6 weeks ago - Business Upturn

Pharma sector stocks down today, March 2: Morepen Lab falls 3.24%, Ajanta Pharma drops 2.32%, Natco Pharma down 2.26%

The Indian pharmaceutical sector experienced a sharp decline on March 2, 2026, with many stocks trading lower in early sessions....

2 months ago - Business Upturn

Ajanta Pharma Ltd (BOM:532331) Q3 2026 Earnings Call Highlights: Strong Revenue Growth and ...

Ajanta Pharma Ltd (BOM:532331) Q3 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic Expansion Plans

3 months ago - GuruFocus

Q3 2026 Ajanta Pharma Ltd Earnings Call Transcript

Q3 2026 Ajanta Pharma Ltd Earnings Call Transcript

3 months ago - GuruFocus

Ajanta Pharma Transcript: Q3 25/26

Q3 FY26 revenue rose 20% YoY, led by strong India and U.S. generics growth, with robust margins and double-digit profit gains. Expansion in sales force, new product launches, and a Biocon partnership for GLP-1s support future growth, while guidance remains positive.

3 months ago - Transcripts

Pharma sector stocks today, Jan 30: Aurobindo Pharma jumps 3%, Ajanta Pharma up 2%, Natco Pharma rises 2%

The Indian pharma sector stocks showed mixed performance on January 30, 2026, as of approximately 10:31 AM IST. The sector...

3 months ago - Business Upturn

India’s Ajanta Pharma eyes Irish manufacturing base

Indian speciality pharmaceutical firm Ajanta Pharma is understood to be eyeing a manufacturing operation in Ireland.

3 months ago - Independent Ireland

Ajanta Pharma shares jump over 4% after signing in-licensing agreement with Biocon

Shares of Ajanta Pharma Ltd. moved over 4% higher in early trade after the company announced a strategic in-licensing agreement...

4 months ago - Business Upturn

Biocon signs out-licensing deal with Ajanta Pharma to market Semaglutide in overseas markets

Biocon Limited has announced the signing of an out-licensing agreement with Ajanta Pharma Ltd for the marketing of its vertically...

4 months ago - Business Upturn

Bharti Airtel, Titan & more: Top stocks on brokers' radar today

Analysts are bullish on Bharti Airtel and Titan, citing strong quarterly results and positive outlooks. Ambuja Cements shows robust EBITDA, while Ajanta Pharma beats estimates with strong internationa...

6 months ago - The Times of India

Ajanta Pharma Ltd (BOM:532331) Q2 2026 Earnings Call Highlights: Strong Revenue Growth Amidst ...

Ajanta Pharma Ltd (BOM:532331) Q2 2026 Earnings Call Highlights: Strong Revenue Growth Amidst Forex Challenges

6 months ago - GuruFocus

Q2 2026 Ajanta Pharma Ltd Earnings Call Transcript

Q2 2026 Ajanta Pharma Ltd Earnings Call Transcript

6 months ago - GuruFocus

Ajanta Pharma Transcript: Q2 25/26

Revenue and profit grew 14% and 12% year-over-year, with robust performance across India, U.S., and Africa. EBITDA margin guidance remains at 27% ±1%, supported by strategic investments and improved working capital efficiency.

6 months ago - Transcripts

Ajanta Pharma to consider interim dividend for FY26 at November 3 board meeting; record date set for November 10

Ajanta Pharma Limited has informed the exchanges that its Board of Directors will meet on Monday, November 3, 2025, to...

6 months ago - Business Upturn

Top stocks to watch today, August 21: Godrej Properties, RailTel, Ajanta Pharma, India Cements and more

Several Indian companies are set to attract attention in today’s trading session following key corporate developments and announcements. Here’s a roundup of the notable stocks and the latest news driv...

8 months ago - Business Upturn

Ajanta Pharma confirms IT raid reports, says business operations remain unaffected

Shares of Ajanta Pharma Ltd. declined nearly 3% on Tuesday, August 19, after reports surfaced of Income Tax department raids at the company’s premises. Business Upturn first reported the development, ...

8 months ago - Business Upturn

Ajanta Pharma shares fall 3% after reports of Income Tax raids

Shares of Ajanta Pharma slipped in trade on Tuesday after news reports suggested that the Income Tax department is conducting raids at the company’s premises. According to Zee Business, search operati...

9 months ago - Business Upturn

Ajanta Pharma in focus as Income Tax raid underway at company premises

Shares of Ajanta Pharma will be in focus after reports emerged that the Income Tax department has conducted raids at the company’s premises, according to Zee Business. Details of the search operations...

9 months ago - Business Upturn

Top stocks to buy today: Stock recommendations for July 31, 2025 - check list

Top stock market recommendations: Nuvama Professional Clients Group's Aakash K Hindocha recommends buying Jindal Steel, Ajanta Pharma, and Godrej Agrovet. Hindocha anticipates range-bound trading for ...

9 months ago - The Times of India